Evidence map›Paper›PMID 42662364›Full record

ArticleJournal of immunotherapy and precision oncology2026

Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report.

Marina Crespo-Cruz, Manuel Rodriguez-Justo, Adam Humphries, Andrew Plumb, Anthony Antoniou, Kevin Monahan, Sarah Runswick, Alessia Capone, Laura Antonucci, Irene Garzia and 5 more

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotherapy and precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04041310 (A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04041310 phase1 / phase2active not recruitingnot on this map

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

TypeinterventionalSponsorNouscom SRLRan2019 to 2026Enrolled115ConditionsSolid Tumor, AdultArmsGAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marina Crespo-CruzDepartment of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0001-4440-9583
Manuel Rodriguez-JustoDepartment of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
Adam HumphriesDepartment of Endoscopy, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
Andrew PlumbDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Anthony AntoniouDepartment of Colorectal Surgery, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
Kevin MonahanDepartment of Gastroenterology, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
Sarah RunswickNouscom AG, Basel, Switzerland.
Alessia CaponeNouscom Srl, Rome, Italy.
Laura AntonucciNouscom Srl, Rome, Italy.
Irene GarziaNouscom Srl, Rome, Italy.
Elisa MicarelliNouscom Srl, Rome, Italy.
Elisa ScarselliNouscom Srl, Rome, Italy.
Anna Morena D'AliseNouscom Srl, Rome, Italy.
Sven GogovNouscom AG, Basel, Switzerland.
Kai-Keen ShiuDepartment of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is an established treatment for mismatch repair-deficient (dMMR) colorectal cancer (CRC), driven by increased neoantigen formation and enhanced responsiveness to immune checkpoint inhibitors. Nous-209 is a polyvalent viral vector immunotherapy under investigation in combination with pembrolizumab in the NOUS-209-01 clinical trial (ClinicalTrials.gov Identifier: NCT04041310) in patients with dMMR CRC. Here, we report on a participant of the NOUS-209-01 trial who achieved a complete pathologic response and significant regression of colonic polyps following treatment with Nous-209 in combination with pembrolizumab and a right hemicolectomy. Genetic testing ruled out Lynch syndrome and mosaicism of Lynch syndrome-associated genes. The patient remains relapse free and under active surveillance 18 months after treatment initiation. Three months after treatment ended, the patient experienced an episode of grade 3 immune-mediated colitis and this improved after infliximab treatment. The clinical and immunologic findings suggest the potential for Nous-209 immunotherapy, in combination with pembrolizumab, to induce regression of both malignant and premalignant colonic lesions. To our knowledge, this is the first report of an immunotherapy combination to reduce premalignant polyps in a patient who does not have Lynch syndrome.

Indexed as

colorectal cancerexperimental cancer medicinesimmunotherapy

Identifiers

PMID42662364
PMCPMC13520590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.